Study on 95% effective dose of dexmedetomidine for sedation in patients with chronic insomnia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063212

Enrollment

Unknown

Registered

2022-09-01

Start date

2023-09-25

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

insomnia disorder

Interventions

experimental group:Intravenous dexmedetomidine

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years; 2. Insomnia for more than 3 months, meets the ICSD-3 diagnostic criteria for chronic insomnia; 3. Sleep latency is longer than 30 minutes; 4. Volunteer to participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Heart, brain, lung, liver and kidney diseases; 2. Sleep apnea syndrome; 3. Restless legs syndrome; 4. Pregnant or lactating patients; 5. Regular night shift work or irregular bedtime; 6. Untreated anxiety, depression or other mental disorders; 7. Those who are allergic to the study drug.

Design outcomes

Primary

Measure	Time frame
Bispectral index;	—

Secondary

Measure	Time frame
modified Aldrete score;onset time;Sedation time;	—

Countries

China

Contacts

Public ContactLi Qingfang

Shanghai Fourth People's Hospital

liqifang2004@126.com+86 136 7183 4019

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026